Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rapid, new test develped for inherited immune deficiency

23.02.2005


Newborn screening could detect bubble boy illness early, save lives



Researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), have developed a new laboratory method that rapidly identifies babies born with inherited forms of severe immune deficiency. The new genetic test, which still must be validated before widespread use, could someday be added to the panel of tests that already screen newborns for a variety of disorders.

The test identifies babies born with Severe Combined Immunodeficiency, or SCID, an illness in which the infant fails to develop a normal immune system. SCID babies can be infected by a wide range of viruses, bacteria and fungi that are normally controlled by a healthy baby’s immune system. If undetected and untreated, SCID typically leads to death before the baby’s first birthday.


Developed in the NHGRI Division of Intramural Research (DIR), the new test can use the same dried blood samples already collected from newborns and would provide the first accurate, high-throughput screen for immune deficiencies. Prior efforts to identify this disorder by counting white blood cells in newborns proved unreliable and expensive.

"This new laboratory technique is an excellent example of how increasingly sophisticated genetic tools can be applied to important public health problems," said NHGRI Scientific Director Eric D. Green, M.D., Ph.D. "Here we have a chance to catch an illness early when treatment is most effective. This new approach provides a rapid, accurate indication of a possible immune problem immediately after birth while the infant is protected by the mother’s antibodies still circulating in the baby’s blood."

If SCID is diagnosed in time, there are effective treatments. One form of the disease can be treated with an injectable medication. All forms of the disorder can be cured through the transplantation of bone marrow if a matching donor can be identified. And finally, SCID may be treated through human gene therapy in which a normal copy of the defective gene may be inserted into the patient’s own blood-forming cells. The first gene therapy experiments in history were carried out at NIH in 1990 in two young Ohio girls with SCID. The patients are alive, continue to do well and are involved in ongoing research at NHGRI.

The sooner a child is diagnosed, the sooner treatment can begin and the more likely it is to be effective. "Too many babies are diagnosed too late," said Jennifer M. Puck, M.D., chief of NHGRI’s Genetics and Molecular Biology Branch. "And some babies develop fatal infections before their condition is recognized. Recent research shows that bone marrow transplants in the first three months of life work better than transplants at a later age. So it is critical to identify affected children immediately after birth. Since the babies lack overt clinical symptoms for some time, a molecular test is a good approach."

The newly developed screening tool exploits a detailed understanding of the maturation of T cells, one of the essential types of white blood cells that make up the immune system. Without a sufficient number of normal T cells, the immune system doesn’t work, just as when the AIDS virus wipes out the same population of immune cells. During normal development, an individual T cell rearranges the gene that produces a so-called antigen receptor on the surface of the cell. The antigen receptor allows the T cell to identify an infectious agent and launch a defensive attack to kill the invader.

While rearranging the receptor gene, the maturing T cell produces a bit of leftover genetic material that forms a ring structure within the cell. Using a quantitative laboratory technique that measures the number of these rings within a blood sample, Dr. Puck’s group was able to differentiate normal infants from those with SCID. In dried blood samples from healthy babies, the team was able to detect an average of 1,000 of these genetic rings; children with SCID had 30 or fewer. "That’s a big difference," she said.

The development of the new test is described in the February issue of The Journal of Allergy and Clinical Immunology. Although the availability of the test raises the question of whether states should begin using it on all newborns, Dr. Puck concluded that the new test is not quite ready for widespread use. It must first be validated.

"Our false positive rate was about 1.5 percent, which is too high to be practical for screening," Dr. Puck said. A baby with a positive test would need to be evaluated to see if he or she was actually sick; a false positive rate of 1.5 percent would mean three out of every 200 newborns would need further testing. "That would be a lot of babies going back to the doctor and a lot of worried parents. We are now working on ways to decrease the number of false positives."

To validate the test, Dr. Puck’s group is collaborating with the newborn screening laboratory of the Maryland Department of Health and Mental Hygiene in Baltimore. The Maryland state lab is supplying some 5,000 blood samples already collected on newborns for the NHGRI lab to test. Although these samples are likely to be normal, they will be used to refine the laboratory procedures and establish quality control. Once the high-throughput screening approach has been validated with this large set of existing samples from Maryland, the NHGRI lab plans to begin prospectively testing newborns from the state. Other state testing laboratories also have expressed interest in participating in the prospective studies.

Although considered a rare disease, SCID is best known to the public from media accounts – and a made-for-TV movie starring John Travolta -- about David, the Bubble Boy, a Texas boy who spent his entire life in a germ-free environment, ultimately dying after a failed bone marrow transplant in early adolescence. No one knows exactly how many babies are born with SCID. Current estimates suggest that 1 in every 50,000 to 100,000 births may be affected, indicating SCID may be about as common as some of the inherited illnesses for which states currently screen all newborns. Experts suspect that many children with SCID die from infections before being diagnosed, so the true incidence of the disease may be even higher. Newborn screening may reveal the true incidence.

Because the new test is still experimental, it is not available to the general public and the cost has yet to be determined. NHGRI is one of the 27 institutes and centers at the National Institutes of Health, which is an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at www.genome.gov

Geoff Spencer | EurekAlert!
Further information:
http://www.nih.gov
http://www.genome.gov

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>